ada standards of care 2025 obesity pharmacotherapy glp-1 recommendations Concise Clinical Guidance: An ACC Expert Consensus Statement on Medical Weight Management for Optimization Cardiovascular Health: A Report of the American College of Cardiology Solution Set Oversight Committee 2025 ACC Scientific Statement on

Typical dosing is 48 mg every 8 hours as needed

Dual GIP/GLP-1 agonists now represent the highest-revenue growth segment in the GLP-1 weight loss drug market at 18.4% CAGR , with tirzepatide generating USD 18.3 billion in 2025 revenue through Zepbound and Mounjaro surpassing Eli Lillys entire insulin franchise within two years of commercial launch

Always rotate the injection site each week to prevent irritation

Providers also evaluate current medications, kidney function, history of pancreatitis, and other factors that influence whether treatment is appropriate

N Engl J Med (2021) 385:50315

The most common side effects were stomach-related problems like nausea, diarrhea, and vomiting